Article: Helping the DEA With Arena Pharmaceuticals' Belviq's Final Scheduling
By: Chris Roberts Seeking Alpha
1) The drug has marginal efficacy, and will be used in combination with phentarmine
2) The drug is like LSD, and will be abused in the same manner.
3) The drug is addictive, and patient population (obese people) have a proclivity to addictions.
4) The drug will be used in large quantities to achieve a "high".
Clinical Pharmacology & Therapeutics
Lorcaserin is a selective and potent serotonin 2C receptor subtype (5-HT2C) agonist under development for the treatment of obesity. This study assessed the drug's abuse potential on the basis of its pharmacological profile. For this purpose, a double-blind, double-dummy, placebo-controlled, randomized seven-way crossover study with single oral doses of lorcaserin (20, 40, and 60 mg), zolpidem (15 and 30 mg), ketamine (100 mg), and placebo was conducted in recreational polydrug users (N = 35). Subjective and objective measures were assessed up to 24 h after the dose. We found that zolpidem and ketamine had significantly higher peak scores relative to placebo on the primary measures as well as on most of the secondary measures. The subjective effects of a 20-mg dose of lorcaserin were similar to those of placebo, whereas supratherapeutic doses of lorcaserin were associated with significant levels of dislike by users as compared with placebo, zolpidem, and ketamine. Perceptual effects were minimal after administration of lorcaserin and significantly lower than after administration of either ketamine or zolpidem. The findings suggest that, at supratherapeutic doses, lorcaserin is associated with distinct, primarily negative, subjective effects and has low
There's the real answer and not some short's wet dream.
The findings suggest that, at supratherapeutic doses, lorcaserin is associated with distinct, primarily negative, subjective effects and has low abuse potential.
There it is in a nutshell as opposed to from a nut job.
This is not what the article says, at all. These are the themes of the negative comments. The DEA can, and should, group these negative comments into "prongs" (their term, as used with Methylone recently).
In response to each prong /group I provided a response and example of the negative comment. With each one, I absolutely believe the claim should be answered "we disagree".
None of these statements is true and the first one is not under the auspice of the DEA to determine; it belongs to the FDA to consider.
Chris Roberts, author (chrisanja on Yahoo)